|Mr. Vincent J. Angotti||CEO & Director||941k||N/A||1968|
|Dr. Pamela Pierce Palmer||Co-Founder, Chief Medical Officer & Director||669.59k||N/A||1963|
|Mr. Raffi Mark Asadorian||Chief Financial Officer||571k||N/A||1969|
|Mr. Lawrence G. Hamel||Chief Devel. Officer||472.06k||13.88k||1952|
|Mr. Anil N. Dasu||Chief Engineering Officer||472.06k||N/A||1963|
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
AcelRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 9.